With the US FDA’s controversial recent decision to approve Biogen and Eisai’s aducanumab – the first approval for a new Alzheimer’s disease…

Since 2000, when Singapore first positioned biomedical research as the fourth pillar of the country’s economy, government funding towards innovative…

Cerecin’s Charles Stacey outlines the company’s progress in expanding its lead asset into migraine and infantile spasms, how its funding strategy…

Cerecin's Charles Stacey looks at the large unmet medical need in diseases of the central nervous system (CNS), the looming socioeconomic burden that…

Dr Charles Stacey, president and CEO of Brain Health company Cerecin, formerly Accera, discusses the rebrand, new investment, the company’s…